Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB1410 + Lenvatinib +/- LB4330 vs Chemotherapy in Advanced Cervical Cancer
NCT07177716Phase 3Not yet recruiting
- Sponsor
- L&L Biopharma Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of LB1410 in Cervical Cancer (CC), sponsored by L&L Biopharma Co., Ltd.. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
LB1410
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07177716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07177716.